Log In
Print this Print this

patisiran (ALN-TTR02, GENZ438027, GZ438027)

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionIV RNAi therapeutic targeting the transthyretin (TTR) gene using second-generation lipid nanoparticle technology
Molecular Target Transthyretin (TTR)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase III
Standard IndicationAmyloidosis
Indication DetailsTreat familial amyloidotic polyneuropathy (FAP); Treat transthyretin (TTR)-mediated amyloidosis
Regulatory Designation U.S. - Fast Track (Treat familial amyloidotic polyneuropathy (FAP));
U.S. - Orphan Drug (Treat familial amyloidotic polyneuropathy (FAP))
Partner Sanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today